Retatrutide.
About Retatrutide
Retatrutide is among the compounds studied in metabolic and weight-regulation research. As the only one of the three major GLP-1-based compounds, retatrutide additionally activates the glucagon receptor alongside GLP-1 and GIP, which studies associate with increased hepatic fat oxidation.
Research Application
Studied in metabolic research as potentially the most potent of the three major GLP-1-based compounds, particularly due to the added glucagon receptor pathway and its associated hepatic fat oxidation. Until any FDA approval, it remains a research compound only.
Important to know
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research Overview
A growing number of preclinical and clinical studies exist for metabolic peptides, though the volume varies significantly by substance.
- Jastreboff AM, et al. NEJM. 2023;389(6):514–526.
- Rosenstock J, et al. The Lancet. 2023;402(10401):529–544. PMID 37385280
- Sanyal AJ, et al. Nature Medicine. 2024;30(7):2037–2048. PMID 38858523
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
Question about Retatrutide?
We reply personally – via email or Telegram.